Indicates the number of subjects with available data for variables in which data were incomplete for some subjects. 
Filgrastim (G-CSF) is commonly combined with either chemotherapy (typically CY) or plerixafor for mobilization of hematopoietic stem cells (HSCs) before auto-SCT for multiple myeloma. These G-CSF-based combinations are often preferred to G-CSF alone because they reliably allow collection of sufficient HSCs for multiple auto-SCTs. 1 Few studies have examined the association between mobilization regimen and post-auto-SCT multiple myeloma outcomes. One retrospective analysis compared outcomes after mobilization with G-CSF+CY vs G-CSF alone and found no PFS difference; 2 this study, however, pre-dated the availability of plerixafor and widespread use of pretransplant lenalidomide and bortezomib. The prospective, randomized study of plerixafor in multiple myeloma patients did not include a chemotherapy-based mobilization arm and did not report longterm multiple myeloma outcomes. 3 Mobilization regimen could plausibly affect outcomes through differential effects on pre-auto-SCT disease burden, graft purity or post-auto-SCT immune reconstitution. For example, chemotherapy-based mobilization may have beneficial anti-myeloma cytotoxic effects, particularly since most multiple myeloma patients now receive little or no preauto-SCT chemotherapy. Alternatively, plerixafor may protect against progression by boosting post-auto-SCT lymphocyte counts 4, 5 but may also mobilize multiple myeloma cells. 6 We therefore examined post-auto-SCT PFS according to mobilization regimen in a single-institution cohort of multiple myeloma patients.
Patients were included in this analysis if they underwent melphalan-conditioned (200 mg/m 2 ) auto-SCT for multiple myeloma at the University of Pennsylvania between January 2010 (when commercially supplied plerixafor was first used at our center) and May 2013 following HSC mobilization/collection with either G-CSF+CY (G/Cy: CY 3 g/m 2 on day 1+G-CSF 10 μg/kg/day starting day 4 or 5 with initiation of HSC collection when the circulating CD34 pos cell count was ⩾ 6/μl) or G-CSF+plerixafor (G/P: as described previously, 3 G-CSF 10 μg/kg/day starting day 1 +plerixafor 0.24 mg/kg/day starting before the first HSC collection on day 4), the two most commonly used regimens at our center during this period. Mobilization regimen was selected by the treating physician with no pre-specified algorithm. Patients were excluded from the analysis if 412 months elapsed between diagnosis and auto-SCT, if 48 weeks elapsed between HSC collection and auto-SCT, if tandem auto-SCT or post-auto-SCT consolidation or experimental immunotherapy was used, or if 41 round of HSC mobilization was required to collect adequate HSCs. Retrospective analysis of this cohort was approved by the Institutional Review Board of the University of Pennsylvania. Table 1 describes the cohort stratified according to mobilization regimen. Noteworthy differences between the two mobilization groups include a higher frequency of patients with high-risk cytogenetic features in the G/P group (50% vs 32%), more frequent use of CY-containing induction in the G/P group (26% vs 6.4%) and slightly longer median interval between diagnosis and auto-SCT in the G/Cy group (7.9 vs 6.8 months). A similar proportion of patients in each group received post-auto-SCT maintenance therapy, but median duration of use was longer in the G/Cy group (11.9 vs 9.5 months); this was not due to disparity in adherence as only one patient in the G/P group discontinued maintenance therapy before censoring. Median PFS was significantly longer in the G/Cy group compared with the G/P group (28.2 vs 19.6 months, P = 0.026; Figure 1a ). High-risk cytogenetic features are a strong prognostic factor in multiple myeloma, although adequate information to assess cytogenetic risk was missing in nearly half the patients in the cohort (42 of 86). Hence, the distribution of cytogenetic risk in our overall cohort is unknown and could have potentially confounded our analysis of PFS. We therefore separately analyzed patients for whom complete cytogenetic data were available.
As expected, patients with high-risk cytogenetic features had inferior median PFS compared with those with standard-risk features (12.9 vs 36.3 months, P = 0.004). When the subset with standard-risk cytogenetic features was analyzed according to mobilization regimen, the G/P group had significantly shorter median PFS (20.0 vs 36.3 months, P = 0.037; Figure 1b ). Among patients with high-risk cytogenetic features, there was no significant PFS difference between those who received G/P vs G/Cy (13.0 vs 11.8 months, P = 0.59; Figure 1c) .
We undertook Cox regression analysis to test the independence of mobilization regimen as a predictor of PFS (see Supplementary  Table) . Variables selected for analysis included mobilization regimen, IgA isotype, attainment of more than 'very good PR' (VGPR) to initial therapy, requirement for more than one induction regimen, absolute lymphocyte count on day 15 and exposure to maintenance therapy (considered as a dichotomous, timedependent variable in which patients contributed time in the 'on maintenance' group while receiving maintenance therapy and the 'off maintenance' group before initiation of and, if applicable, after cessation of maintenance therapy). For these variables, complete data were available for 80/86 subjects. In the multivariable analysis, G/P mobilization regimen remained a statistically significant, independent predictor of shorter PFS in the multivariable analysis (hazard ratio: 2.8, 95% CI: 1.2-6.4, P = 0.02), and the magnitude and statistical significance of the effect was not diminished compared with the univariable analysis (hazard ratio: 2.3, 95% CI: 1.1-4.8, P = 0.03).
Our observation of improved PFS among patients receiving G/Cy mobilization compared with G/P mobilization should be interpreted in view of the significant limitations inherent in retrospective analysis of single-institution cohorts. Particular limitations of this report are the relatively small size of our cohort, the non-random and non-systematic assignment of mobilization regimen and incomplete data in many patients for important prognostic variables such as cytogenetic risk. Although our attempts to address these limitations with subset analysis and multivariable modeling did not identify obvious confounding variables, unmeasured confounders and selection bias may nonetheless be responsible for our findings. Our observations should therefore be regarded as hypothesis-generating.
In summary, in this single-institution, retrospective cohort study, G/Cy mobilization exhibited a significant, independent association with improved PFS compared with G/P mobilization. These results provide rationale for further study on the effect of HSC mobilization regimen on post-auto-SCT multiple myeloma outcomes; ideally, this would be examined in a prospective, randomized trial. 
